Introduction

Current population studies estimate that 0.4–1.1% of adults self-identify as transgender.1 Transgender non-binary (TGNB) patients seek urological consultations for a variety of reasons, including: surgical procedures related to their gender, postoperative complications, sexual health concerns, or for general urological issues. Despite the likelihood that urologists will have clinical encounters with TGNB patients, a Canadian study found that minimal education in residency is focused on this topic.2

The World Professional Association for Transgender Health (WPATH) is an international, multidisciplinary professional association. They put forth a set of evidence and expert opinion-based standards of care (SOC), which are viewed as the prevailing clinical guidelines worldwide.3 The Endocrine Society (ES) also has published guidelines on the treatment of gender-dysphoric/gender-incongruent persons.4 The recommendations and guidelines discussed in this article are based on the SOC set forth by WPATH, in addition to those from ES.

The purpose of this narrative review is to act as a reference for urologists to help understand and provide quality urological care for TGNB patients. We aim to provide pertinent information related to the transition process, hormonal therapies, surgical interventions, and urological issues facing the TGNB population.

Terminology

TGNB individuals have genders that are not aligned with the sex assigned to them at birth. Cisgender refers to individuals whose gender identity matches their sex assigned at birth. For the purposes of simplifying the language used in this review (Table 1), we will be referring to people whose birth-assigned sex was female but identify as male as “transgender men.” People assigned male at birth but who identify as female will be referred to as “transgender women.” It is important for a healthcare provider to inquire what pronouns patients use to ensure the appropriate language is used and to establish trust. Pronouns can include “she/her,” “he/him,” “they/them,” and others. Terminology is ever-changing. Staying current on trans-competent language may lead to improved patient care.

The transition process

Gender dysphoria/incongruence is defined as distress that may accompany the incongruence between one’s gender identity and one’s assigned sex at birth.5 Transition is a term used to describe the process one might take to express their felt gender identity. Transition may involve social, medical, or surgical elements. Social transition can include aspects such as dressing in clothing that reflects their gender identity, name/pronoun change, and changing government identification. Social transitioning alone may alleviate distress from gender dysphoria with improved quality of life and well-being.6 Medical transition generally refers to starting hormone therapies. Surgical transition can include many possible surgeries to alter one’s primary and secondary sex characteristics. There is not one way that a TGNB individual transitions. The process is individualized. For many TGNB patients, social, medical, and surgical transition can greatly improve gender dysphoria.7

In Ontario, the TransPULSE study surveyed 433 participants regarding the transition process.8 Of those surveyed, 30% had not undertaken any steps in the transition process, while 23% were living in their felt gender but without any medical intervention. Forty-six percent of transgender women and 39% of transgender men were currently using hormones for a medical transition. Twenty-three percent reported having completely transitioned, which was self-defined and could include medical or surgical measures.
Of surgical interventions, orchiectomy was most common, reported by 21% of transgender women. Vaginoplasty was reported in 15% of transgender women. In contrast, only 0.4% of transgender men had undergone phalloplasty. The study confirmed this population represents a heterogeneous group in terms of accessing different aspects of transition. This study also suggested that we may be at the “tip of the iceberg” in terms of the numbers of patients going through this process.

### Hormonal and medical therapies

Many patients choose to pursue medical treatments to address their gender dysphoria. Hormonal therapy is generally overseen by the patient’s primary care provider or endocrinologist. Hormonal modulation has quality of life benefits for transgender patients.\(^9,10\) Criteria for the prescription of hormone therapy includes: gender incongruence, capacity to make informed decisions, and reasonable control of associated mental health conditions.\(^11\)

For transgender men, masculinizing hormonal treatment is primarily exogenous testosterone therapy. Transdermal, subcutaneous, and intramuscular (IM) formulations are most commonly used.\(^4\) Target testosterone levels are the same as for cisgender males of the same age. Patients should be screened for contraindications to testosterone therapy, including pregnancy, unstable coronary artery disease, and untreated polycythemia.\(^12\) Patients with a history of estrogen-sensitive malignancy may require a referral to oncology due to the potential for testosterone to be converted to estrogen through aromatization. In addition, patients with underlying polycystic ovary syndrome (PCOS) may need further evaluation due to an elevated risk of side effects with testosterone. Transgender men at risk of becoming pregnant also require effective birth control measures due to the potential teratogenicity of testosterone.

Masculinizing changes on testosterone therapy include increased facial/body hair growth, voice deepening, increased muscle mass, reduced fertility, atrophy of breast tissue, cessation of menses, weight gain, increased libido, possible clitoral virilization, and vaginal atrophy. Hormonal changes occur over variable time frames and to varying degrees. Like any medical therapy, there are potential risks associated with the use of masculinizing hormone therapy (Table 2).

For transgender women, feminizing hormonal therapy requires both estrogen for feminization and an anti-androgen to suppress testosterone levels.\(^4\) Exogenous estrogen works via a central feedback mechanism to reduce androgen pro-

---

### Table 1. Terminology

| Term                               | Definition                                                      |
|------------------------------------|----------------------------------------------------------------|
| Natal sex                          | A person’s anatomic assigned sex at birth                      |
| Gender identity                    | One’s internal sense of having a particular gender, which may or may not correspond to their sex assigned at birth. Many have a binary gender identity and feel that they are either a boy/man or a girl/woman. Others feel that their gender is on a spectrum and do not identify at one end of the gender binary |
| Cisgender                          | When one’s natal sex and gender identity are congruent          |
| Transgender                        | A person’s gender identity and natal sex are discordant         |
| Gender dysphoria/gender incongruence | The distress that may accompany the incongruence between one’s gender identity and one’s assigned sex (American Psychiatric Association, 2013) |
| Sexual orientation                 | Refers to sexual attraction to particular gender(s) regardless of gender identity, i.e., homosexual, bisexual, asexual, pansexual, heterosexual |
| Gender-affirmation surgery (GAS)/gender reconstruction surgery (GRS)/sex reassignment surgery (SRS)/transition-related surgery (TRS) | Surgery performed to change one’s primary or secondary sex characteristics to that of one’s gender identity |

### Table 2. Medical therapies commonly used during the transition process

| Name                        | Indication      | Mechanism                        | Possible side effects/contraindications                                                                 |
|-----------------------------|-----------------|----------------------------------|---------------------------------------------------------------------------------------------------------|
| Testosterone                 | Masculinization | Polycythemia, weight gain, acne, balding, sleep apnea, liver dysfunction, hyperlipidemia, worsening mental health disorders, CAD, CVD, hypertension, type II diabetes, changes in bone density, breast or uterine cancer, cervical cancer, ovarian cancer\(^1,2\) | Hypotension, hyperkalemia |
| Spironolactone               | Antiandrogen    | K⁺ sparing diuretic              | Prolactinoma (when used with estrogen),\(^11\) hepatotoxicity                                         |
| Cyproterone acetate          | Antiandrogen    | GnRH agonist                     |                                                                                                         |
| Exogenous estrogen           | Feminization    | Suppress androgen production via central feedback | Side effect: thromboembolic event, macroprolactinoma, CVD, cholelithiasis, elevated liver enzymes, hypertension, hypertriglycerides, type II diabetes, weight gain, breast cancer\(^1,2\) | Contraindication: breast cancer, previous DVT/PE, cardiovascular or cerebrovascular disease\(^11\) |

CAD: coronary artery disease; CVD: cardiovascular disease; DVT: deep venous thrombosis; GnRH: gonadotropin-releasing hormone; PE: pulmonary embolism.
duction. It may be delivered through a transdermal patch, orally, and intramuscularly. Oral and intramuscular estrogen therapy, as well as higher estrogen doses, may lead to a higher risk of venous thromboembolic events (VTE). Ethinyl estradiol oral therapy carries a high risk of VTE and should not be used. Transdermal estrogen is preferable due to its side effect profile but is costly.

The goals of feminizing hormonal therapy include reducing growth of facial hair, skin softening, inducing breast development and promoting fat and muscle redistribution. Erectile dysfunction, testicular atrophy, and infertility may occur. Hormonal therapy is guided by the normal physiological range of cisgender women and may take 6–18 months. Patients must be screened for contraindications to estrogen therapy, including previous VTE related to a hypercoagulable state, previous hormone-sensitive neoplasm, or end-stage chronic liver disease.

Due to the potential for side effects and to potentiate the effects of estrogen, estrogen is typically used in combination with anti-androgens to minimize the required amount of estrogen to achieve feminizing effects. Gonadotropin-releasing hormone (GnRH) agonists are thought to be as effective as other anti-androgens with possibly lower side effects, but cost is prohibitive. In Canada, spironolactone and cyproterone acetate (Androcur®) are commonly used. Spironolactone works via blockade of the androgen receptor and decreases testosterone levels, while cyproterone acetate works by both central and peripheral inhibition. Spironolactone is often prescribed at much higher doses than what is used for hypertension and patients must be monitored for hyperkalemia. Cyproterone acetate carries concerns regarding hepatotoxicity. 5-alpha reductase inhibitors, such as finasteride and dutasteride, are typically not necessary, as the testosterone levels are almost fully suppressed with estrogen and an anti-estrogen.

Patients on hormonal therapy require ongoing followup, including physical examination and laboratory investigations to assess for hormonal effects and potential complications of treatment. Goals of hormonal manipulation should be to maintain the physiological level required to meet the patient’s desired gender expression.

Transition-related genitourinary surgery

Gender-affirming surgical therapies are summarized in Table 3. Surgery can be a crucial step in alleviating gender dysphoria. There is an accumulation of data that outcomes are overtly positive for improving gender dysphoria, as well as quality of life.

The WPATH SOC has several criteria for patients seeking any genital surgery. Patients undergoing reproductive organ surgery (orchiectomy, hysterectomy, oophorectomy) must have two referral letters to the surgeon and have completed at least one year of hormonal therapy. In general, the writer of the referral letter must be a medical doctor, nurse practitioner, or Masters-level social worker with an interest or prior training in providing transgender healthcare. Provinces may vary in terms of specific requirements for who is eligible to write the referral. The required content of the referral letter is described in Table 4. The same is recommended before undergoing genital surgery, such as metoidioplasty, phallopexy, or vaginoplasty. However, it is also recommended that these patients demonstrate 12 continuous months of living in a gender role that is congruent with their gender identity prior to surgery.

**Orchiectomy**

The benefits of bilateral orchiectomy for transgender women include the ability to discontinue anti-androgen medication and its associated costs, occasional reduction in estrogen dose, increased ability to “tuck,” and increased ease of wearing gender-congruent clothing. Surgery generally involves a single, median raphe incision and removal of both testicles. If vaginoplasty is intended, preservation of the paragonadal

| Table 3. Gender-affirming surgery |
|----------------------------------|
| **Breast/chest surgery** | **Transgender men** | **Transgender women** |
| Subcutaneous mastectomy | | Augmentation mammoplasty |
| **Surgery of the reproductive organs and genitals** | | | |
| Total or subtotal hysterecomy/ salpingo-oophorectomy | **Orchiectomy** | |
| Vaginectomy | | |
| Metoidioplasty with or without urethral reconstruction, typically with scrotoplasty with testicular prosthesis | | |
| Phalloplasty (most commonly a forearm free flap but can also be pedicle flap) typically with urethral reconstruction, scrotoplasty with testicular prosthesis/ possible penile implant | | |
| **Non-chest, non-genital surgery** | Facial feminization surgery, voice surgery, thyroid cartilage reductions, hair transplant |

Modified from WPATH.
fat pad, dartos fascia, and scrotal skin is important for future reconstruction. Patients should be informed of the potential risks of bleeding/hematoma, infection, permanent infertility, worsening erectile dysfunction, poor cosmesis, and palpable cord stump. Patients may opt for an inguinal or subinguinal approach to remove more of the spermatic cord, which if left, may be bothersome. As a dose reduction in hormone therapy may be required postoperatively, communication with the healthcare provider prescribing hormones is important.

**Vaginoplasty**

Penile inversion vaginoplasty (PIV) is the most common technique performed. In brief, the penile skin and prepuce are used to create a neovaginal cavity. A neovagina is created between the rectum and the urethra. Following scrotectomy and orchietomy, the remaining skin is used to create labial folds, while the glans penis is reconstructed to form the neoclitoris. The corporal cavernosal tissue is removed as proximally as possible. In order to minimize complications, the prostate is not removed (Fig. 1). More involved operations may include intestinal or peritoneal vaginoplasty, which allow for the creation of a self-lubricating neovagina.

Permanent hair removal (laser/electrolysis) to the scrotum and penile shaft is encouraged to prevent hair growth in the vaginal canal postoperatively. Some patients may also choose to pursue zero-depth vaginoplasty/vulvoplasty. This obviates the need to dilate and avoids the risk of fistula. Vulvoplasty refers to the creation of a clitoris, clitoral hooding, and labia minora and majora.

There are many potential long-term issues following vaginoplasty, as shown in Table 5. There is a large range of complication rates reported in the literature. Neovaginal stenosis and wound dehisence appear to be the most common complications (12–33%) following penile inversion therapy. As this surgery is only offered in few centers in Canada, long-term postoperative followup is challenging.

**Metoidioplasty and phalloplasty**

There are several goals to consider when approaching genital surgery for transgender men. Functional goals include gaining the ability to stand to void, consolidation of sexual sensation to the neophallus, and ability to achieve an erection satisfactory for penetrative intercourse.

Metoidioplasty uses the virilized clitoral body to create a small phallus, in order to masculinize the phallus while avoiding the morbidity associated with a phalloplasty. Vaginectomy may be performed. During the procedure, the clitoris is degloved and the suspensory ligament divided. The urethra is lengthened using a combination of labia minora and anterior vaginal wall flaps in addition to buccal mucosa. Patients may gain the ability to stand to void via the phallus. The labia majora may be used to create a neocrotum. Testicular implants may also be placed.

Advantages of metoidioplasty include decreased average number of procedures required, good erogenous sensation consolidation to the neophallus, and lower rates of complications compared to phalloplasty. Common urological complaints following metoidioplasty are described in Table 5. Urethrocutaneous fistula occurs in 5–23% of cases, with approximately 50% of these requiring surgical repair. Since the neophallus length is usually only 5–7 cm, penetrative intercourse may be unachievable following metoidioplasty.

Phalloplasty is a complicated, often multistage operation where a flap (usually free flap), is raised to create a neophallus and provide urethral lengthening. There are many different techniques employed based on individual patient needs. One well-studied example is the radial artery forearm free flap (Fig. 2). This technique employs a tube-within-a-tube design for formation of the neo-urethra and a neo-phallus large enough to accommodate an erectile prosthesis during a subsequent surgery. The overall complication rate for phalloplasty is high, estimated to be 40–70%. Common complications are described in Table 5. Complications requiring further surgical reconstruction occurs in approximately 25% of patients following phalloplasty.

---

**Table 4. Recommended content of the referral letters for gender-affirming surgery**

| Patient characteristics | General identifying characteristics |
|------------------------|-----------------------------------|
| Psychosocial assessment | Results of the assessment and any diagnoses |
| Duration of relationship | Duration of the mental health professional’s relationship with the patient (includes type of evaluation, and therapy or counselling) |
| Criteria for surgery | Explanation that the criteria for surgery have been met Brief description of the clinical rationale for supporting the patient’s request for surgery |
| Informed consent | Statement that informed consent (for sharing health information, referral) has been obtained from the patient |
| Coordination of care | Statement that the mental health professional is available for coordination of care and welcomes a phone call to establish this |

---

**Fig. 1. Penile inversion vaginoplasty. Copyright© 2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.**
occur (18–78%) and more than half require surgical revision. Prosthetic erectile implants carry a higher complication rate than in cisgender men, with a 12% infection rate reported in one large study. As well, the flap donor site deformity is an unavoidable downside for this surgery. Phalloplasty (with penile prosthesis) offers a higher likelihood of successful penetrative intercourse and the capacity to stand to void postoperatively. Advantages must be weighed against the longer cumulative surgery and recovery time, and the potential complications. Scrotoplasty with staged placement of testicular implants typically accompanies both metoidioplasty and phalloplasty in transgender men.

Despite the need for multiple surgeries, risk of postoperative complications and potential costs, patients seldom report regret following gender-affirming surgery.

Urological issues in transgender patients

Urological malignancy

Little is known about reproductive malignancies in the transgender population. A retrospective analysis of the North American Association of Central Cancer Registries (NAACR) database from 1995–2013 assessed gender minority cancer patients. Nash et al found a lower proportional incidence ratio of prostate and testicular malignancies for transgender females compared to similar-aged cisgender men. A large
retrospective study of 2306 transgender females reported a prostate cancer prevalence of only 0.04%. Transgender women have castrate levels of testosterone and prostate-specific antigen (PSA) values need to be interpreted with that in mind. Overall, there is a lack of literature regarding the diagnosis, management, and followup of prostate cancer in transgender women.

As the transgender patient population increases, prostate cancer in this population will become a more common urological scenario. Experts recommend following the same screening protocols as for cisgender men. It is unclear how prolonged estrogen and anti-androgen therapy affects prostate cancer risk. In addition, previous gender-affirming surgery may impact the ability to examine the prostate, which may need to be done via examination of the anterior wall of the neovagina.

Testicular cancer is a rare malignancy. Review of the literature found only three case reports of testicular cancer in transgender women on hormonal therapy. As with cis-gendered men, self-examination should be encouraged, and imaging requested if there are any worrisome lesions, especially prior to gender-affirming surgery, as the presence of a testicular mass will alter one's approach to orchiectomy. It is important for urologists to be aware of several barriers to care in this complex patient population to ensure the diagnosis of urological malignancies are not missed.

Fertility

Hormonal and surgical therapies for gender dysphoria have obvious deleterious effects on fertility. Yet, many individuals desire to have genetically related children. Reproductive options should be discussed prior to initiating the transition process. It is imperative that both transgender men and women are counselled on fertility options prior to commencing hormonal or surgical therapies.

For transgender men, options include oocyte or embryo freezing prior to hormonal therapy or surgery. Ideally, this would be completed prior to starting masculinizing hormones. However, there is evidence that ovarian function may recover after exposure to testosterone. The success of this is likely dependent on patient age and length of time on testosterone. In addition, successful pregnancies using assisted reproductive techniques (ART) are possible following cessation of hormone therapies. Some transgender men may want to become pregnant even after having transitioned socially or medically. Literature is emerging on the outcomes of ART for transgender men.

It is important to note that although testosterone may alter ovarian function in transgender men, it is not a form of contraception. Patients who do not want to conceive should be counselled on the importance of contraception.

Transgender women should be counselled on the role of sperm banking prior to starting hormone therapy. Some evidence suggests that even prior to hormonal therapy, some transgender women have abnormal semen parameters in comparison to fertile cisgender men. Certainly, following hormonal therapy, decreased spermatogenesis and fertility occurs. However, cessation of hormone therapy (mean discontinuation period 4.4 months) may allow for recovery of semen parameters comparable to hormone-naive transgender women. One post-orchiectomy study on 135 transgender women who had been treated with hormonal therapy found that nearly 80% had negligible spermatogenesis. Patients must be counselled regarding the irreversibility of infertility following orchiectomy. Little data exists reporting outcomes of ART for transgender women who have chosen sperm cryopreservation.

Prior to transitioning medically or surgically, patients should be advised on the costs associated with sperm/oocyte cryopreservation and made aware that ART is costly and may not be widely available.

Urinary function

Transgender patients may present to urology due to lower urinary tract symptoms for multiple reasons, including complications of gender-affirming surgery. Following gender-affirming surgery, transgender females may develop storage or voiding symptoms related to meatal stenosis or urethral strictures. Incontinence may be a result of urinary retention, stress incontinence, urgency incontinence, or potentially fistula formation. During vaginoplasty, dissection between the rectum and bladder may impact the autonomous nerve supply to the bladder, leading to lower urinary tract dysfunction. Transgender patients may also experience urinary tract infections following reconstructive surgery.

Following phalloplasty in transgender men, the rate of urethral strictures is high, ranging from 25–58%. The most common site of stricture formation is the anastomosis between the native and neourethra, as well as the meatus. Postvoid dribbling may occur due to a lack of bulbospongiosus muscle and corpora spongiosum surrounding the neo-urethra. Urinary tract infections may also occur following genitourinary reconstruction in transgender men.

A full surgical history should be obtained to narrow the differential diagnosis based on associated common complications. Physical exam and measurement of postvoid residual volumes should be completed. If indicated, cystoscopy may need to be performed with sedation or general anesthetic in some patients with gender dysphoria. Caution should be used when navigating the urethra due the high rate of urethral complications in both transgender men and women following gender-affirming surgery. In the case of acute urinary retention, placement of a Foley catheter or suprapubic catheter, if necessary, is appropriate. Contacting
the patient's surgeon to seek direction for further care may be required. If need be, patients should be referred back to the surgeon who performed the GAS, or to a reconstructive urologist comfortable with complex anatomy.

Conclusions

The TGNB population represents a growing, heterogeneous group of patients. The transition process may or may not include social changes, hormonal therapy, and/or surgery to alter primary and secondary sex characteristics. Transgender patients may be referred to urologists for reasons such as surgical procedures related to their gender transition, postoperative complications, sexual health concerns, or for other general urological issues. Despite a deficiency in formalized training during residency and lack of specialized surgical centers in Canada, urologists must be well-versed in transgender healthcare when it comes to urological issues. Urologists have a responsibility to accept patient referrals and provide support. This will allow optimal urological care of this patient population.

Competing interests: The authors do not report any competing personal or financial interests related to this work.

This paper has been peer-reviewed.

References

1. Arcelus J, Bouman WP, Van Den Noortgate W, et al. Systematic review and meta-analysis of prevalence studies in transsexualism. Eur Psychiatry 2015;30:807-15. https://doi.org/10.1016/j.eurpsych.2015.04.005
2. Coutin A, Wright S, Li C, et al. Missed opportunities: Are residents prepared to care for transgender patients? A study of family medicine, psychiatry, endocrinology, and urology residents. Can Med Educ 2018;9:e41-55. https://doi.org/10.34834/cmej.42906
3. The World Professional Association for Transgender Health. Standards of Care for the Health of Transsexual, Transgender and Gender Nonconforming People 7th Version. 2012. Available at: https://www.wpath.org/publications/sc. Accessed on March 18, 2021.
4. Hemmova WC, Cohen-Kettenis PT, Goren L, et al. Endocrine treatment of gender dysphoric/gender incongruent persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017;102:3969-903. https://doi.org/10.1210/jc.2017-01658
5. American Psychiatric Association. What is gender dysphoria. 2020. Available at: https://www.psychiatry.org/patients-families/gender-dysphoria/whatis-gender-dysphoria. Accessed on March 18, 2021.
6. Russell SJ, Pollitt M, Li G, et al. Chosen name use is linked to reduced depressive symptoms, suicidal ideation, and suicidal behavior among transgender youth. J Adolesc Health 2018;63:503-5. https://doi.org/10.1016/j.jadohealth.2018.02.003
7. Winter S, Diamond M, Green J, et al. Transgender people: Health at the margins of society. Lancet 2016;388:390-400. https://doi.org/10.1016/S0140-6736(16)30083-8
8. Scheim AJ, Bauer GR. Sex and gender diversity among transgender persons in Ontario, Canada: Results from a respondent-driven sampling survey. J Sex Res 2015;52:11-14. https://doi.org/10.1007/s11291-014-0935-3
9. Castitte A, Cerpolini S, Akiki S, et al. A prospective study on sexual function and mood in female-to-male transgender patients during testosterone administration and after sex reassignment surgery. J Sex Med 2013;10:321-35. https://doi.org/10.1016/j.jsexmed.2012.03.023
10. Gort-Lazard A, Beumsterk K, Boyer L, et al. Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. J Sex Med 2012;9:531-41. https://doi.org/10.1111/j.1743-6109.2011.02564.x
11. Safer JD, Tangpirich V. Care of Transgender Persons. N Engl J Med 2019;381:2451-60. https://doi.org/10.1056/NEJMcp1903650
12. Carnegie C. Diagnosis of hypogonadism: Clinical assessments and laboratory tests. Rev Urol 2006;8 Suppl 6:53-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472884/
13. Dittrich R, Binder H, Cepati S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005;113:586-92. https://doi.org/10.1055/s-2005-865900
14. Gozo G, Cerpolini S, Martelli V, et al. Cyproterone acetate vs. levonorgestrel in combination with transdermal oestradiol in transwomen: A comparison of safety and effectiveness. Clin Endocrinol (Oxf) 2016;85:239-46. https://doi.org/10.1111/cen.13050
15. De Copparo G, T’soyen G, Beerten R, et al. Sexual and physical health after sex reassignment surgery. Arch Sex Behav 2005;34:679-90. https://doi.org/10.1007/s10508-005-7926-5
16. Murad MH, Elamin MB, Garcia ME, et al. Hormonal therapy and sex reassignment: A systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010;72:214-31. https://doi.org/10.1111/j.1365-2269.2009.03625.x
17. Francis C, Grover E, Potter E, et al. A simple guide for simple orchietomy in transition-related surgeries. Sex Med Rev 2020;8:492-6. https://doi.org/10.1016/j.smrx.2019.11.004
18. Massie JP, Morrison SO, Van Maasdam J, et al. Predictors of patient satisfaction and postoperative complications in penile inversion vaginoplasty. Plast Reconstr Surg 2018;141:911e-21e. https://doi.org/10.1097/PRS.0000000000004427
19. Chen ML, Rechlet P, Poh MM, et al. Overview of surgical techniques in gender-affirming genital surgery. Trans Androl Urol 2018;9:191-208. https://doi.org/10.21037/tau.2018.06.19
20. Horbach SC, Bouman HM, Smit JM, et al. Outcome of vaginoplasty in male-to-female transgenders: A systematic review of surgical techniques. J Sex Med 2015;12:1499-512. https://doi.org/10.1111/jsm.2015.12.0088
21. Lin-Brandt M, Clennon E, Sajadi KP, et al. Metoidioplasty with urethral lengthening: A stepwise approach. Urology 2021;147:319-22. https://doi.org/10.1016/j.urology.2020.09.013
22. Djordjevic ML. Novel surgical techniques in female to male gender confirming surgery. Trans Androl Urol 2018;7:628-38. https://doi.org/10.21037/tau.2018.03.17
23. Djordjevic ML, Stojanovic B, Bizic M. Metoidioplasty: Techniques and outcomes. Trans Androl Urol 2019;8:248-53. https://doi.org/10.21037/tau.2019.09.12
24. Penovic SV, Djordjevic ML. Metoidioplasty: A variant of phalloplasty in female transsexuals. BJU Int 2003;92:981-5. https://doi.org/10.1111/j.1444-410X.2003.04524.x
25. Heston AL, Esmoande ND, Dugu DD, et al. Phalloplasty: Techniques and outcomes. Trans Androl Urol 2019;8:254-65. https://doi.org/10.21037/tau.2019.05.05
26. Doornenbal MT, Hoebbeke P, Caemans E, et al. Penile reconstruction with the radial forearm flap: An update. Handb Chir Anor Rect Plast Chir 2011;43:208-14. https://doi.org/10.1055/s-0030-1267215
27. Wroblewski P, Gustafsson L, Selvaggi G. Sex reassignment surgery for transsexuals. Curr Opin Diabetes 2013;20:570-4. https://doi.org/10.1097/mdo.0b013e318296e3e7
28. Gauthier TW, Audet MA, Ostergaard EC, et al. Postoperative complications following primary penile inversion vaginoplasty among 330 male-to-female transgender patients. J Urol 2018;199:760-5. https://doi.org/10.1016/j.juro.2017.10.013
29. Hoebbeke PB, Decaestecker K, Beyens M, et al. Erectile implants in female-to-male transsexuals: Our experience in 129 patients. Eur Urol 2010;57:534-40. https://doi.org/10.1016/j.eururo.2009.03.013
30. van de Grift TC, Elaut E, Cerwenka SC, et al. Surgical satisfaction, quality of life, and their association after gender-affirming surgery: A followup study. J Sex Med 2018;15:138-48. https://doi.org/10.1016/j.jsm.2018.02.008
31. Goren L, Morkvargler A. Prostate cancer incidence in orchidectomized male-to-female transsexual persons treated with estrogen. Andrologia 2014;46:1154-60. https://doi.org/10.1111/and.12208
32. Ingham ND, Lee R, MaxDemel D, et al. Prostate cancer in transgender women. Urol Oncol 2018;36:518-25. https://doi.org/10.1016/j.urolonc.2018.09.011
33. Kobori Y, Suzuki K, Wohaka T, et al. Mature testicular teratoma with positive estrogen receptor beta expression in a transgender individual on cross-sex hormonal therapy: A case report. LGBT Health 2015;2:81-3. https://doi.org/10.1089/lgbt.2014.0061
36. Chandhoke G, Shayegan B, Hotte SJ. Exogenous estrogen therapy, testicular cancer, and the male to female transgender population: A case report. J Med Case Rep 2018;12:373. https://doi.org/10.1186/s13256-018-1984-6
37. Wolf-Gould CS, Wolf-Gould CH. A transgender woman with testicular cancer: A new twist on an old problem. LGBT Health 2016;3:90-5. https://doi.org/10.1089/lgbt.2015.0057
38. Riggs DW, Bartholomew C. Fertility preservation decision making among Australian transgender and non-binary adults. Reprod Health 2018;15:181. https://doi.org/10.1186/s12978-018-0627-z
39. Hunter MT, Sterrett JJ. Polycystic ovary syndrome: It’s not just infertility. Am Fam Physician 2000;62:1079-88, 90. https://pubmed.ncbi.nlm.nih.gov/10997532/
40. Adeleye AJ, Cedars MI, Smith J, et al. Ovarian stimulation for fertility preservation or family building in a cohort of transgender men. J Assist Reprod Genet 2019;36:2155-61. https://doi.org/10.1007/s10815-019-01558-y
41. Light AD, Obedin-Maliver J, Sevelius JM, et al. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol 2014;124:1120-7. https://doi.org/10.1097/AOG.0000000000000540
42. Marsh C, McCracken M, Gray M, et al. Low total motile sperm in transgender women seeking hormone therapy. J Assist Reprod Genet 2019;36:1639-48. https://doi.org/10.1007/s10815-019-01504-y
43. Adeleye AJ, Reid G, Koo CM, et al. Semen parameters among transgender women with a history of hormonal treatment. Urology 2019;124:136-41. https://doi.org/10.1016/j.urology.2018.10.005
44. Kent MA, Winokar JS, Grataes AB. Effects of feminizing hormones on sperm production and malignant changes: microscopic examination of post orchiectomy specimens in transwomen. Urology 2018;121:93-6. https://doi.org/10.1016/j.urology.2018.07.023
45. Nikolavsky D, Yamaguchi Y, Levine JP, et al. Urologic sequelae following phalloplasty in transgendered patients. Urol Clin North Am 2017;44:113-25. https://doi.org/10.1016/j.ucl.2016.08.006
46. Middelton I, Holden FA. Urological issues following gender reassignment surgery. Br J Nurs 2017;26:528-33. https://doi.org/10.12968bjn.2017.26.18.528

Correspondence: Dr. Ashley R. Cox, Department of Urology, Dalhousie University, Halifax, NS, Canada; ashleycox@Dal.Ca

To answer the multiple-choice questions associated with this article, go to: www.cuasection3credits.org/cuajoctober2021. This program is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by the Canadian Urological Association. Remember to visit MAINPORT (www.mainport.org/mainport/) to record your learning and outcomes. You may claim a maximum of 1 hour of credit.